Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE. A Descriptive Analysis of the Asthma Patient Population in the Emirate of Dubai With Respect to Healthcare Resource Utilization, Costs, and Asthma-related Treatment Pattern

Retrospective Analysis to Describe Patient Profiles, Current Treatment Patterns and Economic Burden for Asthma Patients in UAE.

This Retrospective cohort study with an overall objective of to perform a descriptive analysis of the asthma patient population in the Emirate of Dubai with respect to healthcare resource utilization, costs, and asthma-related treatment patterns and outcome.

Study Overview

• Status: Completed
• Conditions: Asthma

• Study Type: Observational
• Enrollment (Actual): 40541

Contacts and Locations

Study Locations

• United Arab Emirates
  • Dubai, United Arab Emirates
    • Dha Claim

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All patients with a diagnosis of asthma during the identification period will be considered for the analysis

Description

Inclusion Criteria:

• Minimum two claims with asthma diagnosis, 30 days apart, during the identification period
• Minimum 12 months of baseline period
• Age ≥ 18 years on the index date
• Continuous enrolment during the baseline period and at least 180 days of follow-up period; enrolment will be defined based on at least one activity during each 90-day period from the index date

Exclusion Criteria:

• Diagnosis of COPD during the baseline period. Diagnosis of COPD will be defined as ≥1 medical claim with an ICD-10 diagnosis in any position

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Asthma Patients Number	Number of unique asthma patients in the database during December 2015 through November 2018(summarized annually).it will be computed in the follow-up period and will be reported as a percentage and number of visits per person per year (PPPY). Utilization will be considered "all-cause" if the associated medical claim(s) has a diagnosis code in any position for any condition.	1 Year
Asthma-related Cost	Total asthma-related cost reported in the databse during December 2015 through November 2018(summarized annually).It will will be computed in the follow-up period and will be reported as a percentage and number of visits per person per year (PPPY). Utilization will be considered "asthma-related" if the associated medical claim(s) has ICD-10 diagnosis code for asthma as the principal diagnosis	1 Year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Asthma-related hopitalizations cost	Number of asthma related hopistalizations and cost reported in the database during December 2015 through Novemebr 2018(Summairzed annually)	1 Year
Astma-related prescription pattern	Prescription pattern of asthma-related medication by drug class during December 2015 through November 2018	1 Year
Severity of Asthma per total number of patients	Number of patients classified as Mild, moderate and severe asthmatic patinets as per the international guidlines.	1 Year

Collaborators and Investigators

• Sponsor: AstraZeneca

Publications and helpful links

Helpful Links

• CSR Synopsis

Study record dates

Study Major Dates

• Study Start (Actual): August 31, 2019
• Primary Completion (Actual): October 31, 2022
• Study Completion (Actual): October 31, 2022

Study Registration Dates

• First Submitted: April 3, 2019
• First Submitted That Met QC Criteria: May 23, 2019
• First Posted (Actual): May 24, 2019

Study Record Updates

• Last Update Posted (Actual): May 21, 2024
• Last Update Submitted That Met QC Criteria: May 20, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Stress, Psychological; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma; Financial Stress
• Other Study ID Numbers: D2287R00139

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No